Drugs / Tideglusib
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00948259 | Dec 2008 → Nov 2009 | Alzheimer disease | Noscira SA | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05105958 | Dec 2025 overdue | amyotrophic lateral sclerosis | University of Zurich | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02858908 | Jul 2016 → Jan 2018 | myotonic dystrophy type 1 | AMO Pharma Limited | Completed | No outcome recorded |
| Phase 2 | NCT01350362 | Apr 2011 → Jul 2012 | Alzheimer disease | Noscira SA | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT05004129 | Aug 2021 → Dec 2026 expected | congenital myotonic dystrophy | AMO Pharma Limited | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03692312 | Mar 2021 → Apr 2023 | congenital myotonic dystrophy | AMO Pharma Limited | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT01049399 | Dec 2009 → Sep 2011 | progressive supranuclear palsy | Noscira SA | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07119775 | — | congenital myotonic dystrophy | AMO Pharma Limited | Available | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06174220 Comparator | Mar 2025 → Feb 2027 expected | arrhythmogenic right ventricular cardiomyopathy | Hamilton Health Sciences Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT02586935 Comparator | Feb 2016 → Feb 2018 | autism spectrum disorder | Holland Bloorview Kids Rehabilitation Hospital | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tideglusib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01049399 ↗ |
| Known as | AMO-02 | “A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset” PMID 32942085 ↗ Aug 2020 |
| Known as | NP-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545157 ↗ |
| Known as | NP031112 | “NP031112, a Novel GSK3 Inhibitor” NCT00948259 ↗ |
| Known as | TIDEGLUSIB (NP031112) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545157 ↗ |
| Known as | ZENTYLOR NYPTA | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545157 ↗ |
| Action | Inhibit | “a Novel GSK3 Inhibitor” NCT00948259 ↗ |
| Modality | Small molecule | “a small molecule classified as a glycogen synthase kinase-3 (GSK3) inhibitor” NCT06174220 ↗ |
| Route | Oral | “for oral suspension” NCT00948259 ↗ |
| Target | GSK3B | “AMO-02 (tideglusib) inhibits GSK3β activity in preclinical models of type 1 myotonic dystrophy” PMID 32942085 ↗ Aug 2020 |